Literature DB >> 33594213

Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics.

Mayar Allam1, Shuangyi Cai1, Ahmet F Coskun2,3.   

Abstract

Cancers exhibit functional and structural diversity in distinct patients. In this mass, normal and malignant cells create tumor microenvironment that is heterogeneous among patients. A residue from primary tumors leaks into the bloodstream as cell clusters and single cells, providing clues about disease progression and therapeutic response. The complexity of these hierarchical microenvironments needs to be elucidated. Although tumors comprise ample cell types, the standard clinical technique is still the histology that is limited to a single marker. Multiplexed imaging technologies open new directions in pathology. Spatially resolved proteomic, genomic, and metabolic profiles of human cancers are now possible at the single-cell level. This perspective discusses spatial bioimaging methods to decipher the cascade of microenvironments in solid and liquid biopsies. A unique synthesis of top-down and bottom-up analysis methods is presented. Spatial multi-omics profiles can be tailored to precision oncology through artificial intelligence. Data-driven patient profiling enables personalized medicine and beyond.

Year:  2020        PMID: 33594213     DOI: 10.1038/s41698-020-0114-1

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN: 2397-768X


  103 in total

Review 1.  Proliferation, cell cycle and apoptosis in cancer.

Authors:  G I Evan; K H Vousden
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

Review 3.  Cancer genes and the pathways they control.

Authors:  Bert Vogelstein; Kenneth W Kinzler
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

Review 4.  Precision medicine for cancer with next-generation functional diagnostics.

Authors:  Adam A Friedman; Anthony Letai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Cancer       Date:  2015-11-05       Impact factor: 60.716

Review 5.  Circumventing cancer drug resistance in the era of personalized medicine.

Authors:  Levi A Garraway; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

Review 6.  Cancer heterogeneity: implications for targeted therapeutics.

Authors:  R Fisher; L Pusztai; C Swanton
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

Review 7.  Evolving models of tumor origin and progression.

Authors:  Iwona Mitrus; Ewa Bryndza; Aleksander Sochanik; Stanisław Szala
Journal:  Tumour Biol       Date:  2012-04-11

Review 8.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

9.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

Authors:  Sydney M Shaffer; Margaret C Dunagin; Stefan R Torborg; Eduardo A Torre; Benjamin Emert; Clemens Krepler; Marilda Beqiri; Katrin Sproesser; Patricia A Brafford; Min Xiao; Elliott Eggan; Ioannis N Anastopoulos; Cesar A Vargas-Garcia; Abhyudai Singh; Katherine L Nathanson; Meenhard Herlyn; Arjun Raj
Journal:  Nature       Date:  2017-06-07       Impact factor: 49.962

10.  Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.

Authors:  Jay Hocking; Sridurga Mithraprabhu; Anna Kalff; Andrew Spencer
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.